B01AB06 • nadroparin • Blood and blood forming organs | Antithrombotic agents | Heparin group
Nadroparin is a low molecular weight heparin anticoagulant used for the prevention and treatment of deep vein thrombosis and pulmonary embolism. It works by inhibiting factor Xa, preventing the formation of blood clots.
The medication is administered via subcutaneous injection, usually once or twice daily, with the dose adjusted based on the patient's weight and therapeutic indication. Common side effects include bleeding, bruising at the injection site, and thrombocytopenia.
Nadroparin is contraindicated in patients with active bleeding, heparin-induced thrombocytopenia, or hypersensitivity to the active substance. Its use also requires careful monitoring to prevent hemorrhagic complications.
This medication is an effective option for the prevention and treatment of thromboembolic complications, helping to reduce the risk of severe cardiovascular events.
Substance: nadroparin
Date of last drug list: 01-07-2013
Commercial code: W41791001
Concentration: 7600 ui AXa / 0.8ml
Pharmaceutical form: solution for injection
Quantity: 10
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).